Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
Cash & Cash Equivalents
Fate Therapeutics Inc
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fate Therapeutics Inc
NASDAQ:FATE
|
Cash & Cash Equivalents
$121.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
10%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$18.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
8%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$4.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$9.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$9.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
26%
|
CAGR 10-Years
36%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$2.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
See Also
What is Fate Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
121.3m
USD
Based on the financial report for Mar 31, 2024, Fate Therapeutics Inc's Cash & Cash Equivalents amounts to 121.3m USD.
What is Fate Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
10%
Over the last year, the Cash & Cash Equivalents growth was 189%. The average annual Cash & Cash Equivalents growth rates for Fate Therapeutics Inc have been 4% over the past three years , -8% over the past five years , and 10% over the past ten years .